Teleflex (TFX) Aandelenoverzicht
Teleflex Incorporated ontwerpt, ontwikkelt, produceert en levert medische hulpmiddelen voor eenmalig gebruik voor gangbare diagnostische en therapeutische procedures in kritieke zorg en chirurgische toepassingen in de Verenigde Staten, Europa, het Midden-Oosten, Afrika, Azië-Pacific en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 2/6 |
TFX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Teleflex Incorporated Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$130.99 |
| 52 Week Hoogtepunt | US$145.00 |
| 52 Week Laag | US$100.18 |
| Bèta | 0.81 |
| 1 maand verandering | -4.51% |
| 3 maanden verandering | 2.44% |
| 1 Jaar Verandering | 4.05% |
| 3 jaar verandering | -38.00% |
| 5 jaar verandering | -65.45% |
| Verandering sinds IPO | 34,864.98% |
Recent nieuws en updates
Narratiefupdate • Sep 03
TFX: Margin Expansion And Capital Deployment Will Guide Balanced Execution Outlook
Teleflex's analyst fair value estimate has been lifted by about $5 to $153.55 as analysts factor in recent Q2 earnings updates, continuing price target increases across the Street, and a stronger margin outlook despite more cautious revenue assumptions. Analyst Commentary Recent Street research around Teleflex points to a mixed but generally constructive tone, with several firms lifting price targets following Q2 results and company updates.Seeking Alpha • Aug 23
Teleflex: Portfolio Surgery Creates A Better Medtech Compounder
Summary Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility. I expect margin recovery and valuation upside by 2027, contingent on successful integration, cost savings, and renewed Interventional segment growth. Read the full article on Seeking Alpha
Narratiefupdate • Aug 15
TFX: Biotronik Synergies And Portfolio Separation Will Drive 2027 Earnings Inflection
Analysts have lifted the Teleflex fair value estimate to $169 from $160, reflecting updated models after Q2 earnings, a focus on margin expansion, and reassessment of future P/E assumptions and revenue contributions from Biotronik and capital deployment. Analyst Commentary Recent Street research on Teleflex points to a generally constructive tone following Q2 results, with many bullish analysts lifting price targets and highlighting specific growth and margin drivers.Recent updates
Narratiefupdate • Sep 03
TFX: Margin Expansion And Capital Deployment Will Guide Balanced Execution Outlook
Teleflex's analyst fair value estimate has been lifted by about $5 to $153.55 as analysts factor in recent Q2 earnings updates, continuing price target increases across the Street, and a stronger margin outlook despite more cautious revenue assumptions. Analyst Commentary Recent Street research around Teleflex points to a mixed but generally constructive tone, with several firms lifting price targets following Q2 results and company updates.Seeking Alpha • Aug 23
Teleflex: Portfolio Surgery Creates A Better Medtech Compounder
Summary Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility. I expect margin recovery and valuation upside by 2027, contingent on successful integration, cost savings, and renewed Interventional segment growth. Read the full article on Seeking AlphaNarratiefupdate • Aug 15
TFX: Biotronik Synergies And Portfolio Separation Will Drive 2027 Earnings Inflection
Analysts have lifted the Teleflex fair value estimate to $169 from $160, reflecting updated models after Q2 earnings, a focus on margin expansion, and reassessment of future P/E assumptions and revenue contributions from Biotronik and capital deployment. Analyst Commentary Recent Street research on Teleflex points to a generally constructive tone following Q2 results, with many bullish analysts lifting price targets and highlighting specific growth and margin drivers.Narratiefupdate • Jul 31
TFX: Product Approvals And Capital Deployment Plans Will Shape Balanced Forward Outlook
Analysts have nudged their price expectations for Teleflex higher, with the fair value estimate moving from $143.67 to $148.55. They cite recent price target increases linked to new product approvals, capital deployment plans and a range of fresh coverage initiations.Narratiefupdate • Jul 07
TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile
Analysts have lifted their fair value estimate for Teleflex stock from $155 to $160 as they factor in potential benefits from Biotronik-related synergies, capital deployment that is still filtering into Street models, and possible value creation linked to activist involvement. Analyst Commentary Recent research updates around Teleflex highlight a more constructive tone from bullish analysts, with several price target revisions and rating changes aligning around the new US$160 fair value estimate.
Narratiefupdate • Jun 22
TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward
Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.Analyse-artikel • Jun 19
Teleflex (TFX) Stock Could Be 11.6% Undervalued After Q1 Revenue Beat
Teleflex stock reaction centered on earnings, not new debt issue Teleflex (TFX) has been drawing attention after Q1 revenue topped analyst expectations and investors responded positively, even as the company issued new senior notes and reiterated full year EPS guidance below prior estimates. The recent share price move appears more closely linked to Teleflex's earnings update, where revenue performance and progress on its transformation plan supported sentiment, rather than to the sizeable...Narratiefupdate • Jun 06
TFX: Portfolio Reset And Recent Upgrades Will Shape Balanced Forward Outlook
Analysts have raised their fair value estimate for Teleflex from $129.25 to about $143.67, citing a lower required discount rate, an updated view on revenue growth and margins, and a higher assumed future P/E multiple following several recent upgrades and target increases from major firms. Analyst Commentary Recent Street research on Teleflex has leaned constructive, with several firms updating ratings and price targets in quick succession.Narratiefupdate • May 23
TFX: Business Separation And Portfolio Shift Will Drive Future Earnings Repricing
Narrative Update on Teleflex The updated analyst price target for Teleflex moves to $155 from $147, with analysts citing recent upgrades and price target increases, along with the company's ongoing business separation and portfolio optimization efforts, as key supports for the higher fair value and slightly adjusted discount rate and P/E assumptions. Analyst Commentary Recent street research around Teleflex has leaned positive, with several bullish analysts updating views in quick succession.Narratiefupdate • May 02
TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile
Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.Narratiefupdate • Apr 17
TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside
Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.Narratiefupdate • Apr 03
TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook
Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.Narratiefupdate • Mar 20
TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook
Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.Narratiefupdate • Mar 06
TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality
Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.Narratiefupdate • Feb 20
TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook
Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.Narratiefupdate • Feb 06
TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook
Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.Narratiefupdate • Jan 23
TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook
Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.Narratiefupdate • Jan 09
TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook
Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).Narratiefupdate • Dec 20
TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds
Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.Narratiefupdate • Dec 06
TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook
Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.Narratiefupdate • Nov 22
TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures
Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.Analyse-artikel • Nov 09
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Narratiefupdate • Nov 07
TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside
Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.Analyse-artikel • Oct 30
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...Narratiefupdate • Aug 29
Acquisitions And Asian Expansion Will Broaden Healthcare Horizons
Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.Seeking Alpha • Mar 02
Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking AlphaRendement voor aandeelhouders
| TFX | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -5.3% | -5.5% | -0.9% |
| 1Y | 4.1% | -18.1% | 13.9% |
Rendement versus industrie: TFX overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -18.1 % opleverde.
Rendement versus markt: TFX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 13.9 % opleverde.
Prijsvolatiliteit
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: TFX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van TFX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1943 | 15,500 | Jason Weidman | www.teleflex.com |
Teleflex Incorporated ontwerpt, ontwikkelt, produceert en levert medische hulpmiddelen voor eenmalig gebruik voor veelvoorkomende diagnostische en therapeutische procedures in kritieke zorg en chirurgische toepassingen in de Verenigde Staten, Europa, het Midden-Oosten, Afrika, Azië-Pacific en internationaal. Het bedrijf biedt producten voor vasculaire geneeskunde en spoedeisende hulp, waaronder katheters van het merk Arrow, systemen voor katheternavigatie en -tippositionering en intraosseuze toegangssystemen voor intraveneuze therapieën, bloeddrukmeting en afname van bloedmonsters; intraosseuze toegangssystemen bestaande uit EZ-IO intraosseuze vaattoegangssystemen en Arrow FAST1 sternale intraosseuze infusiesystemen; en hemostatische producten, waaronder externe hemostaten en traumaproducten onder het merk QuikClot. Het bedrijf levert ook interventionele producten, waaronder diverse coronaire katheters, structurele hartondersteuningsapparaten en platforms voor perifere interventieproducten; GuideLiner-, Turnpike- en TrapLiner-katheters; MANTA vasculaire afsluitapparaten en Arrow OnControl aangedreven botbiopsiesystemen; en coronaire en perifere medische hulpmiddelen, zoals ballonnen met medicijncoating, stents en ballonkatheters.
Teleflex Incorporated Samenvatting
| TFX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$5.55b |
| Inkomsten(TTM) | -US$25.05m |
| Inkomsten(TTM) | US$2.25b |
2.5x
P/S-verhouding-221.5x
Koers/WinstverhoudingIs TFX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TFX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.25b |
| Kosten van inkomsten | US$1.01b |
| Brutowinst | US$1.24b |
| Overige uitgaven | US$1.27b |
| Inkomsten | -US$25.05m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.59 |
| Brutomarge | 55.11% |
| Nettowinstmarge | -1.11% |
| Schuld/Eigen Vermogen Verhouding | 98.9% |
Hoe presteerde TFX op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.0%
Huidig dividendrendement-239%
UitbetalingsratioBetaalt TFX een betrouwbaar dividend?
Zie TFX dividendgeschiedenis en benchmarks| Teleflex dividenddata | |
|---|---|
| Ex Dividend Datum | Aug 14 2026 |
| Betaaldatum dividend | Sep 30 2026 |
| Dagen tot Ex-dividend | 31 days |
| Dagen tot dividendbetaaldatum | 16 days |
Betaalt TFX een betrouwbaar dividend?
Zie TFX dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/14 11:48 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Teleflex Incorporated wordt gevolgd door 27 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Matthew Taylor | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |